Founded by serial entrepreneurs and seasoned investors.
We back ambitious software-driven and hardware-enabled startups solving real, challenging problems.
Initial check
Up to 3m PLN
Follow-on
Up to 5m PLN
Stage
Pre to early revenue
Geography
Poland / use funds in Poland
Must have
Ambitious, resourceful, and relentless – truly Hard2beat
We don’t invest in B2C, marketplaces, or generic SaaS.
Neuromedical has developed VGuard, a non-invasive vagus nerve stimulation system (tVNS) that has demonstrated significant improvements in cognitive function in Alzheimer’s patients in clinical trials.
We blend firsthand founder experience (scaling businesses to €14M+ ARR, multiple exits) with deep VC expertise (100+ investments). We quickly spot what matters and act fast.
Deep, hands-on advice on global sales, R&D, fundraising, and legal structuring – no fluff, no micromanaging. When things get tough, you’ll want us in your corner.
Access our local and international network of 250+ investors, angels, and industry partners. Whether you’re raising funds, closing deals, or hiring key roles – we connect you fast.
Veteran VC with 40+ pre-seed deals under his belt. Deep expertise in R&D-heavy startups, company-building, and fundraising strategy. Gets technical founders and what they need to thrive.
Former CVC scout connecting startups with corporates. Deep understanding of PoC design, enterprise integration, and tech commercialization. Based in Kraków, always exploring what’s next, especially in deep tech and enterprise.
In the fourth episode of the Hard2beat Podcast, we dive into the world of network security and open source with Robert Olejnik, founder of Defguard.
Raising money for a deeptech startup is tough — long R&D, tricky IP, high risk. Here’s how to build a 10-slide deck that shows your edge and vision.
I invest in hardware. I split my time between factory floors and investment committees, so I see how money works in the real world. The last decade in robotics tells a clear story: Robotics has broken its curse-of-growth loop and is compounding on real deployments.
W trzecim odcinku podcastu Hard2beat zaglądamy do laboratoriów Cogniguard (Neuromedical) – polsko-izraelskiego startupu, który rozwija nieinwazyjną, nocną stymulację nerwu błędnego (tVNS) jako obiecującą terapię spowalniającą, a nawet odwracającą objawy choroby Alzheimera.
Czym jest inwestycyjna jazda po krawędzi, czy warto zakładać się z rynkiem i dlaczego founder powinien wykazać się nieprzeciętną siłą charakteru? Z tymi pytaniami zwracamy się do Macieja Frankowicza, partnera w funduszu Hard2beat.
Nowy fundusz venture capital, Hard2beat, który został zasilony pieniędzmi od PFR Ventures, zaczął inwestować. Z rozmachem, ponieważ przeznaczył 7,5 mln zł na trzy start-upy. W planach ma zainwestowanie w kolejnych pięć do końca tego roku.
